Genomize, founded in 2014, is a well-established global player in the bioinformatics industry, headquartered in Turkey. Boasting the slogan "Scientific excellence for everyone," the company's main thrust lies in genomic data analysis, specifically through its SEQ platform.
The SEQ platform specializes in the analysis of Next Generation Sequencing (NGS) data, offering an end-to-end solution that encompasses everything from raw data to clinical report generation. It automates processes such as data transfer and backup while providing robust tools for data and organization management. The accessibility of the platform from any internet-connected device, alongside its detailed bioinformatics analysis capabilities, makes it a preferred choice for practitioners and researchers alike.
With more than 200,000 samples processed from over 300 centers across more than 20 countries, Genomize has positioned itself as a core bioinformatics solution for hospitals, genetic diagnosis centers, and research institutions focused on NGS data analysis. Notably, no recent investments have been recorded, potentially indicating financial stability or a strategic choice to operate independently.